Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
A randomized clinical trial demonstrates that routine cardiovascular specialist referral for prostate cancer patients improves cholesterol control but does not reduce major cardiovascular events over nearly 6 years.
This study reveals a significant early onset of metabolic syndrome in men with prostate cancer treated with combined ADT and ARPI therapies, highlighting the necessity for multidisciplinary metabolic monitoring and interventions.
A retrospective modeling study of 53 prostate cancer patients found that mechanism-based biomarkers derived from first-cycle PSA dynamics predicted time to progression and survival under adaptive therapy, outperforming standard PSA metrics. The approach could support personalized treatment scheduling.
Mathematical biomarkers derived from initial PSA dynamics effectively predict adaptive therapy outcomes in prostate cancer, enabling personalized treatment strategies that outperform traditional PSA measures.
The Stockholm3 test combined with MRI screening significantly improves detection of clinically significant prostate cancer compared to PSA alone, reducing missed cases and unnecessary biopsies in a population-based study with 2-year follow-
A randomized clinical trial indicates that the GnRH agonist leuprolide significantly accelerates coronary plaque progression compared to the antagonist relugolix in men with prostate cancer, suggesting a potential biological mechanism for d
A large-scale individual patient data meta-analysis suggests that adding hormone therapy to postoperative radiotherapy does not improve overall survival for patients with low PSA levels, prompting a re-evaluation of current treatment standa
This review analyzes the PORTAL study’s nomogram for predicting ADT-free survival in oligorecurrent prostate cancer, synthesizing evidence on PSMA PET-guided SBRT and the clinical utility of risk-based patient selection.
A landmark multicenter study indicates that salvage focal therapy (sFT) achieves long-term cancer-specific survival comparable to salvage radical prostatectomy (sRP) while significantly lowering the risk of major perioperative complications
A randomized clinical trial demonstrates that the GnRH agonist leuprolide leads to significantly greater coronary plaque progression, specifically noncalcified plaque, compared to the antagonist relugolix in men with prostate cancer, offeri
The WOLVERINE individual patient data meta-analysis confirms that metastasis-directed therapy significantly improves progression-free and castration resistance-free survival in oligometastatic prostate cancer, providing high-level evidence
A 20-year cohort study shows that baseline PSA levels in men aged 45-70 are highly predictive of long-term prostate cancer risk, with PSA <1.0 ng/mL indicating a very low 20-year incidence of 3.3%, supporting extended screening intervals
This review analyzes 2025 prostate cancer data, highlighting a 3% annual incidence increase primarily driven by advanced-stage disease. It explores age-specific trends, significant racial inequities in mortality, and the clinical challenges
The MetaCURE trial demonstrates that combining surgery, radiation, and advanced hormonal therapies can achieve deep responses in high-risk prostate cancer, paving the way for faster drug development through intermediate clinical endpoints.
The PROSA trial reveals that a contrast-free biparametric MRI-first screening approach doubles the detection of clinically significant prostate cancer compared to PSA-triggered pathways, while maintaining favorable cost-effectiveness and be
The EMPIRE trials demonstrate that integrating molecular imaging and PET-guided dose escalation significantly improves event-free survival in patients requiring salvage radiotherapy for prostate cancer recurrence.
A validated multimodal AI model using digital pathology and clinical data significantly improves risk stratification for prostate cancer patients with biochemical recurrence, identifying those who derive the greatest benefit from salvage ho
The PRESERVE trial demonstrates that Irreversible Electroporation (IRE) using the NanoKnife System is a safe and effective focal therapy for intermediate-risk prostate cancer, offering high success rates while preserving urinary and sexual
This review synthesizes long-term outcomes and multiethnic data demonstrating that the Stockholm3 test significantly improves the detection of aggressive prostate cancer while reducing overdiagnosis and unnecessary procedures compared to tr
Long-term results from the SAKK 09/10 trial demonstrate that dose-intensified salvage radiotherapy (70 Gy) provides no oncological benefit over conventional dosing (64 Gy) in patients with biochemical recurrence after prostatectomy, while s